multiple system atrophy

multiple system atrophy. It is a rare, adult-onset, and fatal neurodegenerative disease characterized by a variable combination of parkinsonism, cerebellar ataxia, and autonomic nervous system failure. The disorder results from the progressive gliosis and loss of neurons in multiple areas of the central nervous system, accompanied by distinctive glial cytoplasmic inclusions containing misfolded alpha-synuclein. There is no cure, and management focuses on alleviating specific symptoms.

Signs and symptoms

The clinical presentation is categorized into two predominant subtypes: MSA-P, where parkinsonism features like bradykinesia and rigidity dominate, and MSA-C, where cerebellar ataxia with gait disturbance and dysarthria is primary. Nearly all patients develop severe autonomic dysfunction, including orthostatic hypotension, urinary incontinence, and erectile dysfunction. Other common signs include stridor due to laryngeal paralysis, rapid eye movement sleep behavior disorder, and pyramidal tract signs such as hyperreflexia. The Mayo Clinic notes the symptoms often overlap, creating a complex clinical picture distinct from Parkinson's disease.

Causes and pathophysiology

The exact cause remains unknown, with no clear genetic or environmental triggers identified, though rare familial clusters have been reported. The core pathological hallmark is the widespread presence of oligodendroglial cytoplasmic inclusions, primarily composed of misfolded alpha-synuclein, which is also central to dementia with Lewy bodies. These inclusions are associated with profound neurodegeneration and gliosis in key regions like the substantia nigra, putamen, inferior olivary nucleus, cerebellar Purkinje cells, and intermediolateral column of the spinal cord. This pathology disrupts the dopaminergic system, cerebellar cortex, and autonomic pathways.

Diagnosis

Diagnosis is primarily clinical, based on consensus criteria established by the American Autonomic Society and later refined by the Movement Disorder Society. Key supportive investigations include brain MRI, which may show a hot cross bun sign in the pons or putaminal atrophy. Autonomic testing demonstrating severe cardiovagal failure and sympathetic sudomotor failure is crucial. Positron emission tomography scans can reveal reduced dopamine transporter binding. Differential diagnosis primarily involves excluding Parkinson's disease, progressive supranuclear palsy, and pure autonomic failure.

Management

Management is symptomatic and multidisciplinary, involving neurologists, urologists, and physiatrists. Parkinsonism may be treated with levodopa, though response is often poor and transient. Orthostatic hypotension is managed with fludrocortisone, midodrine, and non-pharmacological measures like increased salt intake. Urinary incontinence may require anticholinergic medications or intermittent catheterization. Stridor and sleep disorders are often addressed with continuous positive airway pressure or tracheostomy in severe cases. The National Institutes of Health supports ongoing research into novel therapies.

Prognosis

The disease is relentlessly progressive and incurable, with a median survival of 6 to 10 years from symptom onset. Prognosis is generally poorer than for Parkinson's disease. Death typically results from complications such as bronchopneumonia, sudden cardiac death due to dysautonomia, or aspiration pneumonia. The rate of progression is variable, but the development of severe dysphagia and recurrent laryngeal nerve palsy are often late-stage indicators associated with shortened survival.

Epidemiology

MSA is considered a rare disease, with an estimated prevalence of 3 to 5 cases per 100,000 individuals. Incidence is approximately 0.6 to 0.7 cases per 100,000 person-years. Onset is typically in the sixth decade, with most patients diagnosed between ages 50 and 60. It appears to affect all ethnic groups equally, though some studies from the European Union suggest a slightly higher prevalence in populations of European descent. There is no consistent gender predilection, unlike the male predominance once reported in Shy–Drager syndrome. Category:Neurodegenerative disorders Category:Rare diseases Category:Movement disorders